Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
61°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Repligen Corporation - Common Stock
(NQ:
RGEN
)
149.12
+6.68 (+4.69%)
Streaming Delayed Price
Updated: 3:43 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Repligen Corporation - Common Stock
< Previous
1
2
3
4
5
6
Next >
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
March 12, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.
Via
StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
March 11, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...
Via
StockStory
3 Small-Cap Stocks Skating on Thin Ice
March 06, 2025
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
March 04, 2025
Repligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains.
Via
Benzinga
The Analyst Verdict: Repligen In The Eyes Of 4 Experts
February 21, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Evaluating Repligen: Insights From 6 Financial Analysts
September 26, 2024
Via
Benzinga
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
July 31, 2024
Via
Benzinga
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
February 20, 2025
Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.
Via
Benzinga
Repligen's Q4 Slightly Tops Expectations
February 20, 2025
The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs.
Via
The Motley Fool
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
February 20, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the...
Via
StockStory
Exposures
COVID-19
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
February 19, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.
Via
StockStory
3 Healthcare Stocks Skating on Thin Ice
February 12, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and...
Via
StockStory
Topics
Stocks
Exposures
COVID-19
US Equities
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
November 12, 2024
Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment.
Via
Benzinga
Topics
Earnings
Exposures
Financial
10 Health Care Stocks Whale Activity In Today's Session
November 12, 2024
Via
Benzinga
Wall Street Ticks Up As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What's Driving Markets Friday?
August 16, 2024
Wall Street edged slightly higher on Friday, with major equity indices showing modest gains at midday in New York.
Via
Benzinga
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
August 04, 2024
Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Check if they're in your portfolio!
Via
Benzinga
Here's Why Shares in This Hot Healthcare Stock Surged This Week
August 02, 2024
The bioprocessing market is preparing for a recovery.
Via
The Motley Fool
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 30, 2024
Via
Benzinga
Repligen Lowers Guidance On China Weakness, Analyst Expects
July 30, 2024
Repligen reports Q2 sales of $154.1 million, closely matching the consensus estimate. Adjusted gross margin fell to 49.6% from 50.2%, with an EPS of $0.33. CEO Tony J. Hunt highlights strong Pharma...
Via
Benzinga
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
July 30, 2024
Via
Benzinga
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
June 26, 2024
Via
Benzinga
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
June 26, 2024
Via
Benzinga
Top 3 Health Care Stocks That Could Blast Off In June
June 21, 2024
Via
Benzinga
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 13, 2024
Via
Benzinga
RGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024
May 01, 2024
RGEN stock results show that Repligen missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
April 23, 2024
Via
Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Life Science-Focused Repligen Stock Today?
February 21, 2024
Repligen posts Q4 2023 results. CEO Tony Hunt highlights order strength in Filtration and Analytics. Positive momentum in new modalities; 2024 revenue forecast: $620-$650 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.